Helix BioPharma Announces Q1 2009 Financi... (se of $3000. Higher legal audit and con...)

Helix BioPharma Announces Q1 2009 Financial Results

Date:12/11/2008

se of $3,000. Higher legal, audit and consulting fees in the first quarter of fiscal 2009 were offset by lower wages due to the one time charge of $434,000 relating to the resignation of the Company's Chairman in the first quarter of fiscal 2008.

Amortization of intangible and capital assets

Amortization of intangible assets in the first quarter of fiscal 2009 totaled $3,000 (2008 - $7,000). Amortization of capital assets in the first quarter of fiscal 2009 totaled $64,000 (2008 - $66,000).

Stock-based compensation

Stock-based compensation expense in the first quarter of fiscal 2009 totaled $nil (2008 - $12,000). The stock-based compensation expense in the first quarter of fiscal 2008 relates to the ongoing amortization of compensation costs of stock options granted on June 30, 2005, over their vesting period.

Interest income

Interest income in the first quarter of fiscal 2009 totaled $205,000 (2008 - $104,000) and is mainly the result of higher cash balances.

Foreign exchange loss

Foreign exchange losses in the first quarter of fiscal 2009 totaled $150,000 (2008 - $108,000). Foreign exchange losses are mainly the result of the foreign currency translation of the Company's integrated foreign operation in Ireland. The net assets in Ireland consist mainly of cash and cash equivalents, denominated in Euro dollars, which are used to fund clinical trials of Topical Interferon Alpha-2b in Europe. In addition, U.S. dollar purchases of inventory for distribution in Canada also contributed to the foreign exchange loss.

Income taxes

Income tax expense in the first quarter of fiscal 2009 totaled $30,000 (2008 - $32,000). All income taxes are attributable to the Company's operations in Ireland.

cash flow

Operating activities

N
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.

Post Your Comments:

Helix BioPharma Announces Q1 2009 Financi...(se of $3000. Higher legal audit and con...)